Authors

Latest:

Dr. Higano on the Toxicity of Androgen Receptor Inhibitors in CRPC

Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the toxicity of androgen receptor inhibitors in castration-resistant prostate cancer.

Celestia S. Higano

Latest:

Dr. Higano on Radium-223 for mCRPC

Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Celestia S. Higano, MD

Latest:

Dr. Higano on the GETUG-AFU 16 Trial Results in Prostate Cancer

Celestia S. Higano, MD, discusses the outcomes of the GETUG-AFU 16 and its impact on current practices for prostate cancer.

Celestia S. Higano, MD, FACP

Latest:

Dr. Higano on the State of Immunotherapy in Prostate Cancer

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Celestia S. Higano, MD, FACP, University of Wash

Celestia S. Higano, MD, FACP, University of Washi

Celestia S. Higano, MD, FACP, University of Washing

Celestia S. Higano, MD, FACP, University of Washington

Cem Akin, MD, University of Michigan

Cesar Rodriguez Valdes, MD

Latest:

Dr. Rodriguez on Evolving Role of Small Molecules in Multiple Myeloma

Cesar Rodriguez Valdes, MD, assistant professor of Hematology and Oncology, Wake Forest University Comprehensive Cancer Center, highlights the evolving role of small molecules in multiple myeloma.

Chad Cherington, MD

Latest:

Dr. Cherington on the Use of Immunotherapy and Targeted Therapy in Lung Cancer

Chad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.

Chad Pecot, MD

Latest:

Dr. Pecot on Selecting Between Available Targeted Therapies in NSCLC

Chad V. Pecot, MD, discusses selecting between available targeted therapies in RET-, KRAS-, and MET exon 14 skipping–mutant non–small cell lung cancer.

Chan Cheah, MD

Latest:

Dr. Cheah on Treatment for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Chan Cheah, MD, University of Western Australia, discusses treatment for patients with nodular lymphocyte predominant Hodgkin lymphoma.

Chandan Guha, MBBS, PhD

Latest:

To Radiation With Love: A Bench-to-Bedside Immunotherapy Story

Investigators from Montefiore developed a novel combination that has now demonstrated early-stage efficacy in metastatic lung cancer.

Chandra P. Belani, MD

Latest:

Dr. Chandra Belani on Atezolizumab in NSCLC

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).

Chandra P. Belani, MD, Penn State Cancer Institute

Charalambos (Babis) Andreadis, MD, MSCE

Latest:

Dr. Andreadis on Antibody-Drug Conjugates in DLBCL

Charalambos (Babis) Andreadis, MD, MSCE, discusses the utility of antibody-drugs conjugates in diffuse large B-cell lymphoma.

Charles A. Henderson, MD, Peachtree Consultants

Charles A. Leath III MD

Latest:

Dr. Leath on Agents Under Investigation in Cervical Cancer

Charles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.

Charles A. (Trey) Leath III, MD

Latest:

Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.